Publications
Detailed Information
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, S-W | - |
dc.contributor.author | Oh, D-Y | - |
dc.contributor.author | Im, S-A | - |
dc.contributor.author | Park, S. R. | - |
dc.contributor.author | Lee, K-W | - |
dc.contributor.author | Song, H. S. | - |
dc.contributor.author | Lee, N-S | - |
dc.contributor.author | Lee, K. H. | - |
dc.contributor.author | Choi, I. S. | - |
dc.contributor.author | Lee, M. H. | - |
dc.contributor.author | Kim, M. A. | - |
dc.contributor.author | Kim, W. H. | - |
dc.contributor.author | Bang, Y-J | - |
dc.contributor.author | Kim, T-Y | - |
dc.date.accessioned | 2012-05-25T02:15:16Z | - |
dc.date.available | 2012-05-25T02:15:16Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009-01 | - |
dc.identifier.citation | British Journal of Cancer, Vol.100 No.2, pp.298-304 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.other | 119284 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76452 | - |
dc.description.abstract | This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetuximab 400 mg m(-2) at week 1 and 250 mg m(-2) weekly thereafter until disease progression. Oxaliplatin (100 mg m(-2)) and leucovorin (100 mg m(-2)) were administered as a 2-h infusion followed by a 46-h continuous infusion of 5-fluorouracil (2400 mg m(-2)) every 2 weeks for a maximum of 12 cycles. Biomarkers potentially associated with efficacy were analysed. Among 38 evaluable patients, confirmed response rate (RR) was 50.0% (95% CI 34.1-65.9). Median time-to-progression (TTP) was 5.5 months (95% CI 4.5-6.5) and overall survival (OS) 9.9 months. Eleven patients having tumour EGFR expression by immunohistochemistry with low serum EGF and TGF-alpha levels showed a 100% RR compared to 37.0% in the remaining 27 patients (P<0.001). Moreover, ligand level increased when disease progressed in seven out of eight patients with EGFR expression and low baseline ligand level. No patient exhibited EGFR amplification or K-ras mutations. Gastric cancer patients with EGFR expression and low ligand levels had better outcomes with cetuximab/mFOLFOX6 treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | Nature Publishing Group | - |
dc.title | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1038/sj.bjc.6604861 | - |
dc.citation.journaltitle | British Journal of Cancer | - |
dc.description.citedreference | Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x | - |
dc.description.citedreference | Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492 | - |
dc.description.citedreference | Graziano F, 2008, J CLIN ONCOL, V26, P1427, DOI 10.1200/JCO.2007.12.4602 | - |
dc.description.citedreference | Matsubara J, 2008, BRIT J CANCER, V98, P832, DOI 10.1038/sj.bjc.6604211 | - |
dc.description.citedreference | Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906 | - |
dc.description.citedreference | Cunningham D, 2008, NEW ENGL J MED, V358, P36 | - |
dc.description.citedreference | Lieto E, 2008, ANN SURG ONCOL, V15, P69, DOI 10.1245/s10434-007-9596-0 | - |
dc.description.citedreference | VANCUTSEM E, 2008, J CLIN ONCOL, V26 | - |
dc.description.citedreference | BOKEMEYER C, 2008, J CLIN ONCOL, V26 | - |
dc.description.citedreference | TEJPAR S, 2008, P GASTR CANC S | - |
dc.description.citedreference | TEJPAR S, 2008, J CLIN ONCOL, V26 | - |
dc.description.citedreference | Jonker DJ, 2007, NEW ENGL J MED, V357, P2040 | - |
dc.description.citedreference | Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021 | - |
dc.description.citedreference | Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437 | - |
dc.description.citedreference | Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956 | - |
dc.description.citedreference | Pinto C, 2007, ANN ONCOL, V18, P510, DOI 10.1093/annonc/mdl459 | - |
dc.description.citedreference | LORDICK F, 2007, J CLIN ONCOL, V25 | - |
dc.description.citedreference | LEONCHONG J, 2007, J CLIN ONCOL, V25 | - |
dc.description.citedreference | LLIMPE FLR, 2007, J CLIN ONCOL, V25 | - |
dc.description.citedreference | VANCUTSEM E, 2007, J CLIN ONCOL, V25 | - |
dc.description.citedreference | Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429 | - |
dc.description.citedreference | Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308 | - |
dc.description.citedreference | Tabernero J, 2005, ANN ONCOL, V16, P1740, DOI 10.1093/annonc/mdi355 | - |
dc.description.citedreference | Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556 | - |
dc.description.citedreference | Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9 | - |
dc.description.citedreference | Napieralski R, 2005, CLIN CANCER RES, V11, P3025 | - |
dc.description.citedreference | Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064 | - |
dc.description.citedreference | Cunningham D, 2004, NEW ENGL J MED, V351, P337 | - |
dc.description.citedreference | Gamboa-Dominguez A, 2004, MODERN PATHOL, V17, P579, DOI 10.1038/modpathol.3800085 | - |
dc.description.citedreference | SHIN HR, 2004, CANC RES TREAT, V36, P103 | - |
dc.description.citedreference | Lee SH, 2003, ONCOGENE, V22, P6942, DOI 10.1038/sj.onc.1206749 | - |
dc.description.citedreference | Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504 | - |
dc.description.citedreference | Allgayer H, 2000, J CLIN ONCOL, V18, P2201 | - |
dc.description.citedreference | Therasse P, 2000, J NATL CANCER I, V92, P205 | - |
dc.description.citedreference | Metzger R, 1998, CLIN CANCER RES, V4, P2371 | - |
dc.description.citedreference | SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1 | - |
dc.description.tc | 43 | - |
dc.identifier.wosid | 000262637800012 | - |
dc.identifier.scopusid | 2-s2.0-58749089260 | - |
dc.citation.endpage | 304 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 298 | - |
dc.citation.volume | 100 | - |
dc.identifier.sci | 000262637800012 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, S-A | - |
dc.contributor.affiliatedAuthor | Kim, W. H. | - |
dc.contributor.affiliatedAuthor | Bang, Y-J | - |
dc.contributor.affiliatedAuthor | Kim, T-Y | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | GENE COPY NUMBER | - |
dc.subject.keywordPlus | PLUS IRINOTECAN | - |
dc.subject.keywordPlus | KRAS MUTATIONS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | AMPHIREGULIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Cetuximab | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | epidermal growth factor | - |
dc.subject.keywordAuthor | epidermal growth factor receptor | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | transforming growth factor-alpha | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.